We measured baseline BMP10 plasma concentrations in AF patients who underwent a first elective CA in the prospective Swiss-AF-PVI cohort study. The primary outcome was AF recurrence lasting longer than 30 s during a follow-up of 12 months. We constructed multivariable Cox proportional hazard models to determine the association of BMP10 and AF recurrence. A total of 1112 patients with AF (age 61 ± 10 years, 74% male, 60% paroxysmal AF) was included in our analysis. During 12 months of follow-up, 374 patients (34%) experienced AF recurrence. The probability for AF recurrence increased with increasing BMP10 concentration. In an unadjusted Cox proportional hazard model, a per-unit increase in log-transformed BMP10 was associated with a hazard ratio (HR) of 2.28 (95% CI 1.43; 3.62, P < 0.001) for AF recurrence. After multivariable adjustment, the HR of BMP10 for AF recurrence was 1.98 (95% CI 1.14; 3.42, P = 0.01), and there was a linear trend across BMP10 quartiles (P = 0.02 for linear trend).
The novel atrial-specific biomarker BMP10 was strongly associated with AF recurrence in patients undergoing CA for AF.
NCT03718364; https://clinicaltrials.gov/ct2/show/NCT03718364.
结果:在前瞻性Swiss-AF-PVI队列研究中,我们测量了接受首次选择性CA的AF患者的基线BMP10血浆浓度。主要结果是在12个月的随访中持续超过30s的房颤复发。我们构建了多变量Cox比例风险模型来确定BMP10与房颤复发的相关性。总共1112例房颤患者(年龄61±10岁,74%男性,60%阵发性房颤)纳入我们的分析。在12个月的随访中,374例患者(34%)出现房颤复发。房颤复发的概率随着BMP10浓度的增加而增加。在未经调整的Cox比例风险模型中,对数转化的BMP10每单位增加与房颤复发的风险比(HR)为2.28(95%CI1.43;3.62,P<0.001)相关.经过多变量调整后,BMP10对房颤复发的HR为1.98(95%CI1.14;3.42,P=0.01),并且在BMP10四分位数之间存在线性趋势(线性趋势P=0.02)。
结论:新型心房特异性生物标志物BMP10与接受CA治疗的房颤患者房颤复发密切相关。
背景:NCT03718364;https://clinicaltrials.gov/ct2/show/NCT03718364。